Ignite Creation Date:
2025-12-25 @ 4:48 AM
Ignite Modification Date:
2025-12-26 @ 3:50 AM
Study NCT ID:
NCT00274118
Status:
COMPLETED
Last Update Posted:
2013-11-01
First Post:
2006-01-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077333', 'term': 'Telmisartan'}, {'id': 'D004656', 'term': 'Enalapril'}], 'ancestors': [{'id': 'D001713', 'term': 'Biphenyl Compounds'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001562', 'term': 'Benzimidazoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D004151', 'term': 'Dipeptides'}, {'id': 'D009842', 'term': 'Oligopeptides'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'count': 250}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '1997-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-10', 'completionDateStruct': {'date': '2004-01'}, 'lastUpdateSubmitDate': '2013-10-31', 'studyFirstSubmitDate': '2006-01-09', 'studyFirstSubmitQcDate': '2006-01-09', 'lastUpdatePostDateStruct': {'date': '2013-11-01', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2006-01-10', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2004-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from baseline in glomerular filtration rate GFR after five years of treatment.', 'timeFrame': '5 years'}], 'secondaryOutcomes': [{'measure': 'Change from baseline in GFR after one, two, three and four years of treatment', 'timeFrame': 'Baseline, 1,2,3 and 4 years'}, {'measure': 'Percentage change from baseline in urinary albumin excretion rate', 'timeFrame': 'up to 5 years'}, {'measure': 'Change from baseline in creatinine', 'timeFrame': 'up to 5 years'}, {'measure': 'Incidence of clinical endpoints (including- end-stage renal disease, myocardial infarction, cerebrovascular accident, congestive heart failure)', 'timeFrame': 'up to 5 years'}, {'measure': 'Incidence of all cause mortality', 'timeFrame': 'up to 5 years'}, {'measure': 'Changes in vital signs (DBP, SBP, pulse rate)', 'timeFrame': 'up to 5 years'}, {'measure': 'Number of patients with Adverse Events', 'timeFrame': 'up to 5 years'}, {'measure': 'Physical examination', 'timeFrame': 'up to 5 years'}, {'measure': 'Clinical laboratory parameters', 'timeFrame': 'up to 5 years'}, {'measure': 'Resting 12-lead ECG', 'timeFrame': 'up to 5 years'}]}, 'conditionsModule': {'conditions': ['Hypertension', 'Diabetes Mellitus, Type 2']}, 'referencesModule': {'references': [{'pmid': '38682786', 'type': 'DERIVED', 'citation': 'Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2.'}]}, 'descriptionModule': {'briefSummary': 'To compare the renal consequences of two different approaches to blocking the renin angiotensin system in subjects with hypertension and concurrent Type II diabetes mellitus and diabetic nephropathy.', 'detailedDescription': 'The aims of this study were to compare the renal consequences of two different approaches to blocking the activity of the renin angiotensin system - Angiotensin II antagonism with telmisartan and ACE inhibition with enalapril - in patients with hypertension and concurrent type II diabetes mellitus and diabetic nephropathy.\n\nThe study was designed to investigate albumin excretion rates in the short term, and in the longer term, to assess the outcome with respect to maintenance of renal function (GFR) and incidence of clinical endpoints.\n\nStudy Hypothesis:\n\nAssociation of Hypertension and Diabetes Essential hypertension accounts for the majority of hypertension in people with diabetes, particularly in those with type II diabetes, who constitute more than 90% of those with a dual diagnosis of diabetes and hypertension.\n\nBoth diabetes and hypertension each confer increased cardiovascular risk, and patients with both conditions have more atherogenic risk factors.\n\nAlbumin Excretion as a Therapeutic Marker Microalbuminuria is an early and reliable predictor of diabetic nephropathy in both type I - insulin dependent diabetes mellitus (IDDM) and type II - non insulin dependent diabetes mellitus (NIDDM) patients, nephropathy being characterised by hypertension and an inevitable decline in renal function.\n\nFurthermore, diabetic nephropathy is the single most important cause of end stage renal failure (ESRF) in the western world and over recent years the incidence of ESRF in patients with type II diabetes has dramatically increased.\n\nIn addition to predicting nephropathy, in type II diabetes, microalbuminuria also predicts mortality, the major causes of death being related to cardiovascular disease.\n\nComparison(s):\n\nSelection of an ACE Inhibitor as the Comparative Agent Findings in preclinical studies of animals with diabetes mellitus suggest that ACE inhibitors reduce glomerular damage by one or more mechanisms independent of their antihypertensive effects. Glomerular efferent arteriolar tone is increased in diabetic animals and as a result there is an increase in transcapillary hydraulic pressure. These alterations may decrease the functional integrity of the glomerular capillary wall. In rats with diabetes, the long term administration of an ACE inhibitor diminishes the functional and morphologic evidence of glomerular injury and decreases glomerular transcapillary pressure. Removal of the tonic constrictor effect of angiotensin II on efferent arterioles would be expected to lower glomerular intracapillary pressure while preserving renal plasma flow.\n\nAngiotensin II antagonists appear to be as effective as ACE inhibitors in delaying the progression of renal injury in animal models of diabetes.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '35 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Male or female subjects between the ages 35 and 80 years.\n2. Current ACE inhibitor therapy for a minimum period of 3 months prior to study entry.\n3. Confirmed diagnosis of type II diabetes:\n\n * Subjects currently treated by diet or diet and oral hypoglycaemic drugs, OR\n * Subjects currently treated with insulin, with a history of onset of diabetes after the age of 40 and a body weight in excess of ideal body weight at the time of diagnosis, and treated with oral agents for a minimum period of two years\n4. On treatment diastolic blood pressure of \\< 95 mmHg.\n5. Documentation of a normal renal ultrasound within previous 6 months prior to inclusion (alternate methods eg pyelography, renal isotope method was also acceptable).\n6. Mean of three consecutive overnight urinary albumin excretion rates \\> 20 and \\< 1000 g/min at the end of the pre-treatment observation period. (A minimum of two of the three samples must be \\> 20 g/min.)\n7. Glycosylated haemoglobin (HbA 1c) \\< 10%.\n8. Serum creatinine \\< 140 mol/L.\n9. Glomerular filtration rate (GFR) \\> 70 ml/min/1.73 m2.\n10. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Type I diabetes mellitus.\n2. Pre-menopausal women (last menstruation \\< 1 year prior to start of screening period):\n\n * Who were not surgically sterile (tubal ligation, hysterectomy) or\n * Who were not practising acceptable means of birth control (and do not plan to continue using this method throughout the study). Acceptable methods of birth control include oral, implantable or injectable contraceptives.\n * Who had a positive serum pregnancy test at baseline.\n3. Afro-Caribbean subjects.\n4. Mean seated SBP \\> 180 mmHg.\n5. Hepatic dysfunction as defined by the following laboratory parameters: SGPT(ALT) or SGOT(AST) \\> 1.5 times the upper limit of normal.\n6. Known causes of renal dysfunction other than diabetic nephropathy.\n7. Subjects who had a solitary kidney or known renal artery stenosis.\n8. NYHA functional class CHF II - IV.\n9. Known drug or alcohol dependency.\n10. Subjects receiving any investigational therapy within one month of providing written informed consent.\n11. Known hypersensitivity to telmisartan or ACE inhibitors or to any component of the formulation.\n12. Subjects with a history of suspected angioedema related to ACE inhibitor therapy.'}, 'identificationModule': {'nctId': 'NCT00274118', 'briefTitle': 'DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril', 'organization': {'class': 'INDUSTRY', 'fullName': 'Boehringer Ingelheim'}, 'officialTitle': 'DETAIL = Diabetics Exposed to Telmisartan And enalapIL: A Randomised, Double-blind, Parallel-group Comparison of the Renal and Antihypertensive Effects of Telmisartan and Enalapril in Subjects With Mild to Moderate Hypertension and Concurrent Type II Diabetes Mellitus and Diabetic Nephropathy', 'orgStudyIdInfo': {'id': '502.236'}}, 'armsInterventionsModule': {'interventions': [{'name': 'telmisartan', 'type': 'DRUG'}, {'name': 'enalapril', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'zip': 'DK-2000', 'city': 'Frederiksberg', 'country': 'Denmark', 'facility': 'Apopleksiafsnittet', 'geoPoint': {'lat': 55.67938, 'lon': 12.53463}}, {'zip': 'DK-1900', 'city': 'Frederiksberg C', 'country': 'Denmark', 'facility': 'Boehringer Ingelheim Investigational Site'}, {'zip': 'DK-2900', 'city': 'Hellerup', 'country': 'Denmark', 'facility': 'Lungemedicinsk Forskning', 'geoPoint': {'lat': 55.73204, 'lon': 12.57093}}, {'zip': 'DK-3400', 'city': 'Hillerød', 'country': 'Denmark', 'facility': 'Medical Dept. B0642', 'geoPoint': {'lat': 55.92791, 'lon': 12.30081}}, {'zip': 'DK-2650', 'city': 'Hvidovre', 'country': 'Denmark', 'facility': 'Hvidovre Hospital', 'geoPoint': {'lat': 55.64297, 'lon': 12.47708}}, {'zip': '6000', 'city': 'Kolding', 'country': 'Denmark', 'facility': 'Gynækologisk/obstetrisk afd.', 'geoPoint': {'lat': 55.4904, 'lon': 9.47216}}, {'zip': '05850', 'city': 'Hyvinkää', 'country': 'Finland', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 60.63333, 'lon': 24.86667}}, {'zip': 'FIN-40100', 'city': 'Jyväskylä', 'country': 'Finland', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 62.24147, 'lon': 25.72088}}, {'zip': 'FI-70211', 'city': 'Kuopio', 'country': 'Finland', 'facility': 'Kuopion yliopistollinen sairaala, Keuhkoklinikka', 'geoPoint': {'lat': 62.89238, 'lon': 27.67703}}, {'zip': '11100', 'city': 'Riihimäki', 'country': 'Finland', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 60.73769, 'lon': 24.77726}}, {'zip': '33520', 'city': 'Tampere', 'country': 'Finland', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 61.49911, 'lon': 23.78712}}, {'zip': '5223 GV', 'city': "'s-Hertogenbosch", 'country': 'Netherlands', 'facility': 'Bosch Medicentrum', 'geoPoint': {'lat': 51.69917, 'lon': 5.30417}}, {'zip': '3584 CX', 'city': 'Utrecht', 'country': 'Netherlands', 'facility': 'Dept. of Internal Medicine', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}, {'zip': 'N-4841', 'city': 'Arendal', 'country': 'Norway', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 58.46151, 'lon': 8.77253}}, {'zip': 'N-2050', 'city': 'Jessheim', 'country': 'Norway', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 60.14151, 'lon': 11.17515}}, {'zip': 'N-7620', 'city': 'Skogn', 'country': 'Norway', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 63.70374, 'lon': 11.19262}}, {'zip': 'N-4011', 'city': 'Stavanger', 'country': 'Norway', 'facility': 'Hjertelaget Research Foundation', 'geoPoint': {'lat': 58.97005, 'lon': 5.73332}}, {'zip': '575 81', 'city': 'Eksjö', 'country': 'Sweden', 'facility': 'Medicinkliniken', 'geoPoint': {'lat': 57.66643, 'lon': 14.97205}}, {'zip': '251 87', 'city': 'Helsingborg', 'country': 'Sweden', 'facility': 'Medicinkliniken', 'geoPoint': {'lat': 56.04673, 'lon': 12.69437}}, {'zip': '254 67', 'city': 'Helsingborg', 'country': 'Sweden', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 56.04673, 'lon': 12.69437}}, {'zip': '455 30', 'city': 'Munkedal', 'country': 'Sweden', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 58.46634, 'lon': 11.67345}}, {'zip': '573 83', 'city': 'Tranås', 'country': 'Sweden', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 58.03717, 'lon': 14.9782}}, {'zip': '451 40', 'city': 'Uddevalla', 'country': 'Sweden', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 58.34784, 'lon': 11.9424}}, {'zip': '751 25', 'city': 'Uppsala', 'country': 'Sweden', 'facility': 'Samariterhemmets sjukhus', 'geoPoint': {'lat': 59.85882, 'lon': 17.63889}}, {'zip': '574 28', 'city': 'Vetlanda', 'country': 'Sweden', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 57.42887, 'lon': 15.07762}}, {'zip': 'CV9 1EU', 'city': 'Atherstone', 'country': 'United Kingdom', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 52.57536, 'lon': -1.54693}}, {'zip': 'CF62 7EB', 'city': 'Barry', 'country': 'United Kingdom', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 51.39979, 'lon': -3.2838}}, {'zip': 'B18 7QH', 'city': 'Birmingham', 'country': 'United Kingdom', 'facility': 'Dept. of Diabetes', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'B9 5SS', 'city': 'Birmingham', 'country': 'United Kingdom', 'facility': 'Department of Respiratory Medicine', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'BH7 7DW', 'city': 'Bournemouth', 'country': 'United Kingdom', 'facility': 'Royal Bournemouth Hospital', 'geoPoint': {'lat': 50.72048, 'lon': -1.8795}}, {'zip': 'NE1 7RU', 'city': 'Newcastle upon Tyne', 'country': 'United Kingdom', 'facility': 'Finance Office (Research Unit)', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}, {'zip': 'NN1 5BD', 'city': 'Northampton', 'country': 'United Kingdom', 'facility': 'Northampton General Hospital', 'geoPoint': {'lat': 52.25, 'lon': -0.88333}}, {'zip': 'NN5 7AQ', 'city': 'Northampton', 'country': 'United Kingdom', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 52.25, 'lon': -0.88333}}, {'zip': 'CV10 7DJ', 'city': 'Nuneaton', 'country': 'United Kingdom', 'facility': 'Diabetes Centre,', 'geoPoint': {'lat': 52.52323, 'lon': -1.46523}}, {'zip': '94304-5786', 'city': 'Palo Alto', 'country': 'United Kingdom', 'facility': "Lucille Packard Children's Health Services at Stanford"}, {'zip': 'CF72 9AA', 'city': 'Pont-y-clun', 'country': 'United Kingdom', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 51.52162, 'lon': -3.39145}}, {'zip': 'CV22 5PX', 'city': 'Rugby', 'country': 'United Kingdom', 'facility': 'Diabetes Centre', 'geoPoint': {'lat': 52.37092, 'lon': -1.26417}}], 'overallOfficials': [{'name': 'Boehringer Ingelheim Study Coordinator', 'role': 'STUDY_CHAIR', 'affiliation': 'Boehringer Ingelheim Ltd./Bracknell'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Boehringer Ingelheim', 'class': 'INDUSTRY'}}}}